Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

• Egile Nagusiak: Xiaomin Wan (Egilea), Xiaohui Zeng (Egilea), Liubao Peng (Egilea), Ye Peng (Egilea), Qiao Liu (Egilea), Lidan Yi (Egilea), Xia Luo (Egilea), Qijian Deng (Egilea), Chongqing Tan (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov model wasdeveloped to evaluate the cost and effec...